# Identification of Molecular Subtypes of B-Cell Acute Lymphoblastic Leukemia in Mexican Children by Whole-Transcriptome Analysis

**Authors:** Norberto Sánchez-Escobar, María de los Ángeles Romero-Tlalolini, Haydeé Rosas-Vargas, Elva Jiménez-Hernández, Juan Carlos Núñez Enríquez, Angélica Rangel-López, José Manuel Sánchez López, Daniela Rojo-Serrato, América Mariana Jasso Mata, Efraín Abimael Márquez Aguilar, Janet Flores-Lujano, Juan Carlos Bravata-Alcántara, Jorge Alfonso Martín-Trejo, Silvia Jiménez-Morales, José Arellano-Galindo, Aurora Medina Sanson, Jose Gabriel Peñaloza Gonzalez, Juan Manuel Mejía-Aranguré, Minerva Mata-Rocha

PMC · DOI: 10.3390/ijms26147003 · 2025-07-21

## TL;DR

This study identifies molecular subtypes of B-cell acute lymphoblastic leukemia in Mexican children using RNA sequencing, revealing key mutations and gene fusions for better diagnosis and treatment.

## Contribution

The study provides a detailed molecular classification of B-ALL in Mexican pediatric patients using whole-transcriptome analysis.

## Key findings

- High hyperdiploidy was the most common molecular subtype in Mexican B-ALL patients.
- RNA-seq successfully detected gene fusions and mutations across various B-ALL subtypes.
- Ph-like subtype showed specific mutations and CRLF2 overexpression, while DUX4 had PDGFRa variants.

## Abstract

B-lineage acute lymphoblastic leukemia (B-ALL) is classified into more than 20 molecular subtypes, and next-generation sequencing has facilitated the identification of these with high sensitivity. Bulk RNA-seq analysis of bone marrow was realized to identify molecular subtypes in Mexican pediatric patients with B-ALL. High hyperdiploidy (27.3%) was the most frequent molecular subtype, followed by DUX4 (13.6%), TCF3::PBX1 (9.1%), ETV6::RUNX1 (9.1%), Ph-like (9.1%), ETV6::RUNX1-like (9.1%), PAX5alt (4.5%), Ph (4.5%), KMT2A (4.5%), and ZNF384 (4.5%), with one patient presenting both the PAX5alt and low hypodiploidy subtypes (4.5%). The genes TYK2, SEMA6A, FLT3, NRAS, SETD2, JAK2, NT5C2, RAG1, and SPATS2L harbor deleterious missense variants across different B-ALL molecular subtypes. The Ph-like subtype exhibited mutations in STAT2, ADGRF1, TCF3, BCR, JAK2, and NRAS with overexpression of the CRLF2 gene. The DUX4 subtype showed mutually exclusive missense variants in the PDGRFA gene. Here, we have demonstrated the importance of using RNA-seq to facilitate the differential diagnosis of B-ALL with successful detection of gene fusions and mutations. This will aid both patient risk stratification and precision medicine.

## Linked entities

- **Genes:** TYK2 (tyrosine kinase 2) [NCBI Gene 7297], SEMA6A (semaphorin 6A) [NCBI Gene 57556], FLT3 (fms related receptor tyrosine kinase 3) [NCBI Gene 2322], NRAS (NRAS proto-oncogene, GTPase) [NCBI Gene 4893], SETD2 (SET domain containing 2, histone lysine methyltransferase) [NCBI Gene 29072], JAK2 (Janus kinase 2) [NCBI Gene 3717], NT5C2 (5'-nucleotidase, cytosolic II) [NCBI Gene 22978], RAG1 (recombination activating 1) [NCBI Gene 5896], SPATS2L (spermatogenesis associated serine rich 2 like) [NCBI Gene 26010], STAT2 (signal transducer and activator of transcription 2) [NCBI Gene 6773], ADGRF1 (adhesion G protein-coupled receptor F1) [NCBI Gene 266977], TCF3 (transcription factor 3) [NCBI Gene 6929], BCR (BCR activator of RhoGEF and GTPase) [NCBI Gene 613], PDGFRA (platelet derived growth factor receptor alpha) [NCBI Gene 5156], CRLF2 (cytokine receptor like factor 2) [NCBI Gene 64109]
- **Diseases:** B-cell acute lymphoblastic leukemia (MONDO:0004947)

## Full-text entities

- **Genes:** NT5C2 (5'-nucleotidase, cytosolic II) [NCBI Gene 22978] {aka GMP, NT5B, PNT5, SPG45, SPG65, cN-II}, TCF3 (transcription factor 3) [NCBI Gene 6929] {aka AGM8, AGM8A, AGM8B, E2A, E47, ITF1}, SPATS2L (spermatogenesis associated serine rich 2 like) [NCBI Gene 26010] {aka DNAPTP6, SGNP}, RAG1 (recombination activating 1) [NCBI Gene 5896] {aka RAG-1, RNF74}, NRAS (NRAS proto-oncogene, GTPase) [NCBI Gene 4893] {aka ALPS4, CMNS, N-ras, NCMS, NRAS1, NS6}, ADGRF1 (adhesion G protein-coupled receptor F1) [NCBI Gene 266977] {aka GPR110, KPG_012, PGR19, hGPCR36}, JAK2 (Janus kinase 2) [NCBI Gene 3717] {aka JTK10}, KMT2A (lysine methyltransferase 2A) [NCBI Gene 4297] {aka ALL-1, ALL1, CXXC7, GAS7, HRX, HTRX}, PAH (phenylalanine hydroxylase) [NCBI Gene 5053] {aka PH, PKU, PKU1}, TYK2 (tyrosine kinase 2) [NCBI Gene 7297] {aka IMD35, JTK1}, ZNF384 (zinc finger protein 384) [NCBI Gene 171017] {aka CAGH1, CAGH1A, CIZ, ERDA2, NMP4, NP}, FLT3 (fms related receptor tyrosine kinase 3) [NCBI Gene 2322] {aka CD135, FLK-2, FLK2, STK1}, CRLF2 (cytokine receptor like factor 2) [NCBI Gene 64109] {aka CRL2, CRLF2Y, TSLPR}, SETD2 (SET domain containing 2, histone lysine methyltransferase) [NCBI Gene 29072] {aka HBP231, HIF-1, HIP-1, HSPC069, HYPB, KMT3A}, SEMA6A (semaphorin 6A) [NCBI Gene 57556] {aka HT018, SEMA, SEMA6A1, SEMAQ, VIA}, BCR (BCR activator of RhoGEF and GTPase) [NCBI Gene 613] {aka ALL, BCR1, CML, D22S11, D22S662, PHL}, STAT2 (signal transducer and activator of transcription 2) [NCBI Gene 6773] {aka IMD44, ISGF-3, P113, PTORCH3, STAT113}, DUX4 (double homeobox 4) [NCBI Gene 100288687] {aka DUX4L}
- **Diseases:** -Cell Acute Lymphoblastic Leukemia (MESH:D054218), Ph (MESH:D010677), B-ALL (MESH:D054198)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Figures

3 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12295331/full.md

---
Source: https://tomesphere.com/paper/PMC12295331